GSK Pharma is a pharmaceutical company involved in many therapeutic areas where they provide healthcare solutions
Revenue declined 6 % YoY in 3Q to Rs.780 Cr. mainly due to recall of ranitidine products. Company reported losses of Rs 660 Cr. on account of one-time financial impairment of Rs.750 Cr. Key promoted brands formed 60% of sales as compared to 20% up until 2QFY20
Its decision to stop selling ‘Zinetac’ brand (~6% of sales) is likely to have an adverse impact on near-term growth. The recently launched ‘Nucala’ has witnessed strong traction YTD and remains one of GLXO’s promising products.
Company’s P/E may drop due to industry-wide slowdown in the anti-infective category with improved hygienic conditions and lower intensity of epidemics.
Disclaimer: The above report is compiled from information available on public platforms. inChat team advises users to check with certified experts before taking any investment decisions.
Found this insight useful?
Please share with your friends and family as well. You can also subscribe to one of our channels listed at the bottom of this page.